Acadia Healthcare Company Inc (ACHC)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -21,667 | -18,272 | 270,537 | 278,317 | 273,139 | 282,293 | 277,320 | 241,755 | 190,635 | -663,315 | -692,443 | -695,878 | -672,132 | 100,286 | 105,854 | 112,915 | 108,923 | -211,460 | -207,794 | -197,098 |
| Total stockholders’ equity | US$ in thousands | 2,781,970 | 2,712,560 | 2,921,020 | 2,839,600 | 2,812,730 | 2,743,710 | 2,663,040 | 2,574,510 | 2,517,490 | 2,434,450 | 2,356,590 | 2,298,000 | 1,899,460 | 2,606,640 | 2,503,340 | 2,464,170 | 2,505,380 | 2,420,690 | 2,422,350 | 2,403,340 |
| ROE | -0.78% | -0.67% | 9.26% | 9.80% | 9.71% | 10.29% | 10.41% | 9.39% | 7.57% | -27.25% | -29.38% | -30.28% | -35.39% | 3.85% | 4.23% | 4.58% | 4.35% | -8.74% | -8.58% | -8.20% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-21,667K ÷ $2,781,970K
= -0.78%
Acadia Healthcare Company Inc's return on equity (ROE) has exhibited variability over the past eight quarters. The ROE ratio represents the company's profitability in relation to shareholders' equity.
From Q1 2022 to Q2 2023, Acadia Healthcare Company Inc's ROE showed a generally positive trend, with the ratio ranging from 9.26% to 10.41%. However, there was a significant decline in ROE in Q4 2023, dropping to -0.78%. This negative ROE indicates the company's net income was insufficient to cover shareholders' equity, raising concerns about profitability and operational efficiency.
It is important for investors and stakeholders to closely monitor Acadia Healthcare Company Inc's financial performance to understand the factors influencing its ROE fluctuations and to assess the company's ability to generate returns for shareholders from their investment in the company.